Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2010
02/23/2010CA2335461C Calcium channel blockers
02/23/2010CA2329930C Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
02/23/2010CA2319916C Use of dhea, its precursors or its metabolic derivatives as a depigmentation agent
02/23/2010CA2297115C Treatment of diabetes with thiazolidinedione and sulphonylurea
02/23/2010CA2232288C Treating niddm with rxr agonists
02/23/2010CA2154698C Therapeutic inhibitor of vascular smooth muscle cells
02/20/2010CA2682471A1 Method and dosage regimens for eliminating a chemical substance in blood
02/18/2010WO2010019967A1 Fluorescent cdk inhibitors for treatment of cancer
02/18/2010WO2010019963A2 Na channels, disease, and related assays and compositions
02/18/2010WO2010019953A1 High concentration local anesthetic formulations for treating non-neuropathic pain
02/18/2010WO2010019930A1 Urea derivatives as inhibitors of map kinases
02/18/2010WO2010019924A1 Composition and methods for the design and development of metallo-enzyme inhibitors
02/18/2010WO2010019915A1 Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
02/18/2010WO2010019914A2 Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
02/18/2010WO2010019911A2 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions
02/18/2010WO2010019910A1 Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
02/18/2010WO2010019909A1 Pyrrole inhibitors of s-nitrosoglutathione reductase
02/18/2010WO2010019905A1 Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
02/18/2010WO2010019903A1 Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
02/18/2010WO2010019899A1 cMET INHIBITORS
02/18/2010WO2010019847A2 Aptamer inhibition of thrombus formation
02/18/2010WO2010019832A2 Amide-extended crosslinking compounds and methods for use thereof
02/18/2010WO2010019830A1 Glucagon antagonists
02/18/2010WO2010019828A1 Glucagon receptor antagonists
02/18/2010WO2010019796A1 Heterocyclic amide derivatives as ep4 receptor antagonists
02/18/2010WO2010019786A1 HDAC4, HDAC5, HDAC6, HDAC7, AND HIF1α MODULATION OF RETINAL CELL SURVIVAL
02/18/2010WO2010019777A1 Local anti-infective agent for treatment of nail fungal infections
02/18/2010WO2010019775A2 Methods of treating ras driven cancer in a subject
02/18/2010WO2010019772A2 Oxadiazole-2-oxides as antischistosomal agents
02/18/2010WO2010019718A2 Carrier nanoparticles and related compositions, methods and systems
02/18/2010WO2010019716A1 Aabb-poly(depsipeptide) biodegradable polymers and methods of use
02/18/2010WO2010019701A2 Diaryl urea derivatives
02/18/2010WO2010019698A2 Inhibition of calicivirus (norovirus)
02/18/2010WO2010019659A1 Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use
02/18/2010WO2010019646A1 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof
02/18/2010WO2010019611A2 Bridged polycyclic compound based compositions for topical and oral applications
02/18/2010WO2010019606A1 Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
02/18/2010WO2010019574A1 A micro-rna that promotes vascular integrity and uses thereof
02/18/2010WO2010019560A1 Deuterated derivatives of donepezil
02/18/2010WO2010019557A1 N-phenyl-2-pyrimidineamine derivatives
02/18/2010WO2010019549A2 Indoprofen derivatives for promoting bone growth
02/18/2010WO2010019547A1 Imine derivatives as cannabinoid receptor ligands
02/18/2010WO2010019540A1 Treatment of pulmonary arterial hypertension
02/18/2010WO2010019536A1 Therapeutic compounds
02/18/2010WO2010019511A2 Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
02/18/2010WO2010019489A2 Method for making terpene derivatives
02/18/2010WO2010019473A1 Aurora kinase modulators and methods of use
02/18/2010WO2010019450A2 Synergizing active compounds for treating inflammation and other conditions
02/18/2010WO2010019446A1 Nucleic acid aptamers
02/18/2010WO2010019435A2 Solid states of atorvastatin potassium
02/18/2010WO2010019434A1 Methods to treat and screen for agents to treat obesity
02/18/2010WO2010019417A2 Chymase inhibitors
02/18/2010WO2010019398A1 Two phase bioactive formulations
02/18/2010WO2010019393A1 Pyrimidine derivatives for treatment of alzheimer's disease
02/18/2010WO2010019392A1 Purine derivatives for treatment of alzheimer's disease
02/18/2010WO2010019391A1 N-heterocyclic m1 receptor positive allosteric modulators
02/18/2010WO2010019276A2 Method and formulation for treating adverse biological conditions
02/18/2010WO2010019271A1 Fluorescent regulators of rassf1a expression and human cancer cell proliferation
02/18/2010WO2010019270A1 Modulation of prion expression
02/18/2010WO2010019255A1 Compositions containing aminoalkanes and aminoalkane derivatives
02/18/2010WO2010019225A1 Pharmaceutical composition
02/18/2010WO2010019212A2 Methods for enhancing energy metabolism
02/18/2010WO2010019211A1 Compositions and methods for influencing satiety, lipid metabolism, and fat utilization
02/18/2010WO2010019210A2 Halofuginone analogs for inhibition of trna synthetases and uses thereof
02/18/2010WO2010019208A1 Flavin derivatives
02/18/2010WO2010019206A1 Antifungal agents
02/18/2010WO2010019204A1 Antifungal agents
02/18/2010WO2010019155A1 Gentle, non-irritating, non-alcohoholic skin disinfectant
02/18/2010WO2010019101A1 A crystalline form of 4- (5-{ (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } - 4 -methyl- 4h- 1, 2,4- triazol-3-yl) pyridine
02/18/2010WO2010019100A1 A new crystalline form of 4- (5- { (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4h-l, 2, 4- triazol-3-yl) pyridine
02/18/2010WO2010019099A1 2-hydroxy-ethanesulfonate salt
02/18/2010WO2010019098A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist
02/18/2010WO2010019097A1 Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient
02/18/2010WO2010019059A1 Veterinary preparation
02/18/2010WO2010019057A1 The treatment of hearing loss
02/18/2010WO2010019034A1 Use of carvacrol for treating inflammatory diseases
02/18/2010WO2010018867A1 Di-substituted benzopyrane compound
02/18/2010WO2010018866A1 Stabilized pharmaceutical composition
02/18/2010WO2010018856A1 Prophylactic/ameliorating or therapeutic agent for cannabinoid receptor-related disease
02/18/2010WO2010018855A1 Drug sustained release agent, adsorbent, functional food, mask, and adsorptive sheet
02/18/2010WO2010018837A2 Protein cross-linking inhibitor
02/18/2010WO2010018836A2 Polyglutamine aggregation inhibitor
02/18/2010WO2010018800A1 Acetyl pyrrolidinyl indole derivative
02/18/2010WO2010018777A1 Odor-controlling method
02/18/2010WO2010018652A1 Agent for promoting neuronal differentiation and method therefor
02/18/2010WO2010018614A1 Hydrophilic amino acid-containing preparation having improved taste
02/18/2010WO2010018596A2 Stable injectable oil-in-water docetaxel nanoemulsion
02/18/2010WO2010018549A2 Therapeutic compositions containing macitentan
02/18/2010WO2010018547A1 Aminoquinoline compounds
02/18/2010WO2010018484A1 New uses of diisopropylamine derivatives
02/18/2010WO2010018481A1 2-amino pyrimidine compounds as potent hsp-90 inhibitors
02/18/2010WO2010018474A2 Novel glucopyranose derivatives, preparation thereof, and biological uses thereof
02/18/2010WO2010018435A1 Amide glycosides
02/18/2010WO2010018418A1 Formulation based on micronized clinoptilolite as therapeutic agent providing highly bioavailable silicon
02/18/2010WO2010018408A2 Pharmaceutical compositions
02/18/2010WO2010018352A1 Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
02/18/2010WO2010018329A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
02/18/2010WO2010018328A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
02/18/2010WO2010018327A1 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof
02/18/2010WO2010018280A1 Use of p2x7 receptor antagonists to promote axonal growth and ramification
1 ... 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 ... 7860